Last updated: February 16, 2026
Overview
NDC 00143-9139 corresponds to Atenolol Oral Tablets, 25 mg, a beta-blocker used primarily for hypertension and angina. The drug is FDA-approved and widely prescribed, with a substantial generic market segment.
Market Size and Trends
-
Global Market Value: The global atenolol market was valued at approximately USD 150 million in 2022 and projected to grow at a compound annual growth rate (CAGR) of 3-4% through 2028, driven by increased prevalence of cardiovascular diseases (CVD) and rising healthcare access in emerging markets [1].
-
US Market Share: The U.S. accounts for about 50-60% of the global atenolol market, with annual sales exceeding USD 70 million in 2022. The prevalence of hypertension affects over 47% of American adults, supporting consistent demand [2].
-
Competitive Landscape: The market comprises multiple generic producers and some branded formulations. Peak competition has optimized prices, especially in generics, but new formulations or formulations with improved delivery could shift market dynamics.
Pricing Data
-
Average Wholesale Price (AWP): Wholesale prices for 30-day supplies (30 tablets of 25 mg) range from USD 3.50 to USD 5.50 depending on supplier and pharmacy margins [3].
-
Reimbursement and Medicaid Pricing: Reimbursement rates are approximately 20% less than AWP, with Medicaid and other insurers often negotiating significant discounts.
-
Patient Cost-Sharing: Out-of-pocket expenses for patients typically range from USD 4 to USD 8 per month, depending on insurance coverage.
Regulatory and Patent Status
-
Patent Expiry: As a generic drug, the primary patent barriers expired in the early 2000s. No active patents restrict manufacturing.
-
Regulatory Filings: No recent significant regulatory filings or new formulations are indicated, meaning the current market primarily relies on existing generic versions.
Price Projections
-
Short-term (Next 2 Years): Prices are expected to remain stable, with slight reductions driven by increased competition. Generics commoditize rapidly, so price erosion of 5-10% annually is typical.
-
Long-term (3-5 Years): New developments like extended-release formulations or combination therapies could marginally increase prices if clinically validated. However, for standard 25 mg tablets, prices will likely decline gradually, stabilizing near USD 3.00 to USD 4.00 per 30-day supply.
-
Impact of Policy: Healthcare policy shifts toward cost containment and bulk purchasing may further pressure prices downward.
Market Drivers and Risks
-
Drivers: Growing CVD prevalence, generic market expansion, increased healthcare coverage.
-
Risks: Market saturation, patent challenges in other markets, drug shortages, and potential shifts toward newer agents with better side-effect profiles.
Conclusion
The atenolol 25 mg tablet market remains stable with a two-tiered pricing structure: wholesale prices hover around USD 4, with retail and insurance pricing slightly higher. State and federal payers dominate reimbursement, pressuring prices downward over time. Limited innovation and patent expiration suggest continued commoditization, further depressing prices.
Key Takeaways
- NDC 00143-9139 (atenolol 25 mg) operates in a large, mature, and commoditized market.
- Current OTC and insurance reimbursement models keep patient costs low.
- Market prices are expected to stabilize or decrease modestly over the next five years.
- Growth hinges on CVD prevalence and insurance coverage expansion.
- Lack of new formulations indicates limited price volatility unless regulatory or market shifts occur.
FAQs
1. How does generic competition influence atenolol prices?
Generic competition drives prices down rapidly. Once patents expire, multiple manufacturers enter the market, creating price pressure and reducing wholesale and retail costs.
2. Are there significant regulatory hurdles affecting the market?
No. As a generic product with no recent patent protections, regulatory hurdles are minimal. FDA approval is well established, and approvals are routine.
3. Can new formulations alter price projections?
Yes. If a new, more effective or better-tolerated formulation surpasses standard atenolol, it could command higher prices. Currently, no such formulations are on the horizon.
4. What impact might policy changes have?
Policy measures favoring cost containment and negotiating drug prices can further reduce prices, particularly within government-funded programs like Medicaid.
5. How does market growth compare to other beta-blockers?
Atenolol's market growth parallels beta-blockers overall but is constrained by generic competition and the emergence of cardioselective and vasodilatory beta-blockers with better safety profiles.
Sources
-
Grand View Research. "Beta-Blockers Market Size, Share & Trends." 2022.
-
CDC. "High Blood Pressure Facts." 2023.
-
Medicare and private insurer formularies. 2023.
